Effect of dexmedetomidine for prevention of acute kidney injury after cardiac surgery: an updated systematic review and meta-analysis

Xing Liao, Qinxue Hu, Qianxiu Chen, Jing Jia, Yong-Hong Liao and Jianguo Feng

Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Laboratory of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China

ABSTRACT

Background: Acute kidney injury (AKI) is a serious complication related to cardiac surgery. Several studies have been conducted to investigate the effect of dexmedetomidine administration on AKI prevention.

Objective: To assess if dexmedetomidine is associated with a protective effect of renal function after cardiac surgery. And the aim of conducting this meta-analysis is to summarize the literature and determine the clinical utility of dexmedetomidine administration in patients undergoing cardiac surgery.

Methods: PubMed, Cochrane Library, and EMBASE databases were comprehensively searched for all randomized controlled trials (RCTs) published before 1 December, 2021 that investigated the effect of dexmedetomidine on AKI prevention.

Results: Our analysis included 16 studies involving 2148 patients. Compared with the control group, dexmedetomidine administration significantly reduced AKI incidence (OR, 0.47; 95% CI, 0.36–0.61; p < 0.00001; I² = 26%) and the length of stay in the intensive care unit (ICU) but did not alter mortality rate, length of stay in the hospital, and mechanical ventilation time. Furthermore, the incidence of delirium among patients treated with dexmedetomidine was significantly decreased.

Conclusion: Dexmedetomidine administration has a positive effect on preventing AKI and postoperative delirium after cardiac surgery and significantly reduces the length of stay in the ICU.

ARTICLE HISTORY
Received 4 January 2022
Revised 27 June 2022
Accepted 29 June 2022

KEYWORDS
Dexmedetomidine; cardiac surgery; renal function; meta-analysis

Introduction

Acute kidney injury (AKI) is a serious complication of cardiac surgery with an estimated incidence of 20% [1,2]. It is the second most common type of AKI in the intensive care unit, following sepsis-related AKI [3]. Coronary artery bypass graft and cardiac valve replacement can cause AKI because they are always accompanied by renal ischemia-reperfusion injury (I/RI), elevated sympathetic activity, and hemodynamic instability. Despite steps to prevent AKI, a standard for preventing AKI after cardiac surgery is lacking.

Dexmedetomidine, an α2-adrenoreceptor agonist, has been widely used in anesthesia procedures and intensive care. It inhibits inflammation, alleviates postoperative delirium, and exhibits neuroprotective effects. AKI incidence decreases after the use of dexmedetomidine in cardiac surgery. However, it remains unclear if dexmedetomidine can ameliorate the harmful effects of cardiac surgery on renal function. Six additional single-center randomized controlled trials have been concluded since the previous meta-analysis was published. Therefore, the present meta-analysis was conducted to provide updated information on the efficacy of dexmedetomidine on renal function after cardiac surgery.

Methods

Search strategy and selection criteria

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and is registered at the International Prospective Register of Systematic Reviews.
Cochran's Q test and Higgins’ $I^2$ statistical test were used to assess the statistical heterogeneity of the pooled results [4]. If $0\% \leq I^2 < 25\%$, the results showed no heterogeneity; if $25\% \leq I^2 < 50\%$, the results showed a low level of heterogeneity; if $50\% \leq I^2 < 75\%$, the results showed a medium level of heterogeneity; if $75\% \leq I^2 \leq 100\%$, the results showed a high level of heterogeneity. Risk of bias assessment was done using the Cochrane Collaboration tool (Cochrane, London, UK).

Begg’s test and Egger’s test were used to determine publication bias, and a $p$-value $< 0.1$ indicated significant bias. Trim-and-fill computation was performed to estimate the effect of publication bias on the interpretation of the results. $p < 0.05$ (two-sided) indicated statistical significance. We used REVMAN (version 5.4; Cochrane Collaboration, Oxford, UK) and Stata (version 12.0; Stata Corp LP) for statistical analyses.

**Results**

**Study characteristics**

The literature search identified 1640 articles of which 16 articles [5–20] ultimately met the inclusion criteria (Figure 1). The characteristics of the 16 studies that involved 2148 participants are summarized in Tables 1 and 2. For postoperative outcomes, AKI incidents were reported in all studies. AKI was defined based on three definitions, including RIFLE [6,10,12,20], AKIN [8,13,18], KDIGO [7,11,12,16], and a diagnostic criterion of Cr $> 115$ μmol/L [17]. Four studies did not mention the specific criteria used to define AKI [5,9,15,19].

The risk of bias graph (Figure 2) shows two studies rated as high risk for attrition bias, in which complete outcome data were not available. Supplementary Figure 3 shows no significant asymmetry in the funnel plot, which means no significant publication bias.

**Effect of dexmedetomidine on AKI**

In a pooled analysis of all 16 studies, the overall incidence of AKI was 13.78% (dexmedetomidine group, 105/787; control group, 191/1071). The incidence of AKI was significantly reduced after perioperative dexmedetomidine treatment (OR, 0.47; 95% CI, 0.36–0.61; $p < 0.00001$; $I^2 = 26\%$. Figure 3). No publication bias was noted according to Begg’s test ($p > 0.1$) and Egger’s test ($p > 0.1$).

Subgroup analyses to identify the effect of a potential source of heterogeneity on AKI were performed by classifying these included studies according to gender (proportion of male $\geq 50\%$ vs. $< 50\%$), age (year, $\geq 60$ vs. $< 60$), duration of CPB (min, $\leq 80$ vs. $> 80$), control drugs

**Study selection and data extraction**

Two independent investigators (LX and HQX) reviewed the published studies and extracted data. If there were disagreements, the third investigator (CQX) resolved. RCTs involving cardiac surgery and treatment with dexmedetomidine during the perioperative period and reporting AKI incidence, regardless of the criteria AKIN, KDIGO, and RIFLE, were considered eligible for inclusion. Observational or retrospective studies were excluded. If there was more than one comparison eligible for inclusion criteria in one study, all of the comparisons would be included and defined as different groups. The Cochrane risk of bias tool was used for assessing the quality of the included studies. The following data were extracted from selected studies: total number of patients and their characteristics (age, sex, proportion of patients with diabetes, and proportion of hypertension), cardiac surgical procedures, cardiopulmonary bypass (CPB) time, control drugs, and the dosage of dexmedetomidine. The primary outcome was AKI incidence after cardiac surgery within 7 days. Secondary outcomes were as follows: all-cause mortality (within 30 days), mechanical ventilation (MV) duration, and the length of stay in ICU and hospital.

**Statistical analysis**

The incidence of AKI after cardiac surgery, mortality, mechanical ventilation duration, the length of stay in ICU, and the length of stay in the hospital were analyzed. Data were pooled from all eligible RCTs and the Mantel–Haenszel method was used to calculate the risk ratio (RR) with 95% confidence intervals (CIs) for these dichotomous outcomes. A pooled estimate of RR was computed using the DerSimonian and Laird random-effects model. This model provides an appropriate assessment of the average treatment effect when studies are statistically heterogeneous, and it typically yields relatively wide CIs resulting in a more conservative statistical claim.
(placebo vs nonplacebo), loading dose (using or not), continuous infusion dose (>0.4 vs. 0.4 ≤ μg/kg/h), time of dexmedetomidine administration (pre/intraoperation vs. post-operation), diabetes (≥25 vs. <25%), hypertension (≥50 vs. <50%), and surgical procedures (CABG only vs combined surgery), as shown in Table 2. The results indicated no significant differences in the AKI incidence.

Mortality rate after dexmedetomidine treatment
A mortality rate of 1.5% was reported (dexmedetomidine group, 6/651; control group, 14/648). No significant difference was noted between the two groups (OR, 0.48; 95%CI, 0.19–1.24; p = 0.13; I² = 0%, Figure 4)

The length of stay in ICU, MV duration, and length of stay in hospital after dexmedetomidine treatment
Perioperative dexmedetomidine treatment could significantly reduce the length of stay in ICU (OR, −2.04; 95%CI, −3.60 to −0.49; p = 0.01; I² = 100%, Supplementary Figure 1). MV duration in ICU and hospital stay did no significantly differ between the two groups.

Effect of dexmedetomidine on the incidence of adverse events during the perioperative period
The incidence of delirium was significantly reduced by administration of dexmedetomidine (p < 0.001), while no significant change in the incidence of arrhythmias (p = 0.06), bradycardia (p = 0.08), hypotension (p = 0.41), and stroke (p = 1.00) was observed (Figure 5).

Discussion
The present meta-analysis indicated that the administration of dexmedetomidine can reduce AKI incidence during the perioperative period in cardiac patients. Compared with previous meta-analysis [21], our subgroup analysis indicated no significant differences in age and the usage time of dexmedetomidine. Perioperative dexmedetomidine treatment significantly reduced the length of stay in the ICU. Mortality rate and MV duration did not differ significantly between the groups. Moreover, dexmedetomidine treatment significantly reduce the incidence of delirium, but the incidence of arrhythmias, bradycardia, hypotension, and stroke in the perioperative period was not significantly altered.
| Study          | Country | Surgery                  | Age      | No. of Patients (Dex vs Control) | Loading DOSE | Dexmedetomidine dose | Control | Time and duration                                                                 | AKI definition | Clinical End Point           |
|---------------|---------|--------------------------|----------|---------------------------------|--------------|---------------------|---------|-----------------------------------------------------------------------------------|----------------|-----------------------------|
| Ammar 2016    | Egypt   | Combined                 | Adult    | 25 vs. 25                       | 1 ug/kg      | 0.5 ug/kg/h         | Placebo | Started 5min before CPB and continued 6 h after surgery                           | NA             | AKI; MV duration; ICU stay; hospital stay; mortality |
| Balkanay (High dose) 2015 | Turkey | CABG                     | Senior   | 29 vs. 28                       | NA           | 0.04–0.5 ug/kg/h/h | Placebo | Started after arrived ICU and last for a maximum of 24 h                           | RIFLE          | AKI; MV duration; ICU stay; hospital stay |
| Balkanay (Low dose) 2015 | Turkey | CABG                     | Senior   | 31 vs. 28                       | NA           | 0.04–0.5 ug/kg/h/h | Placebo | Started after arrived ICU and last for a maximum of 24 h                           | RIFLE          | AKI; MV duration; ICU stay; hospital stay |
| Cho 2016      | Korea   | Combined                 | Senior   | 100 vs. 100                     | NA           | 0.4 ug/kg/h         | Placebo | Started after anesthetic induction and continuing for 24 h after surgery          | AKIN           | AKI; mortality              |
| Djaiani 2016  | Canada  | Combined                 | Senior   | 91 vs. 92                       | 0.4 ug/kg    | 0.2–0.7 ug/kg/h/h   | Propofol| Started upon arrival to ICU and continued until extubation                      | NA             | AKI; MV duration; ICU stay; hospital stay |
| Jo 2017       | Korea   | Atrial or ventricular defect repair | Pediatric | 15 vs. 14                      | 0.5 ug/kg    | 0.5 ug/kg/h         | Placebo | Started after anesthesia induction and continued to the end of CPB              | AKIN           | AKI                         |
| Kim 2020      | Korea   | Combined                 | Pediatric| 71 vs. 68                       | 1 ug/kg      | 0.5 ug/kg/h         | Placebo | Started after induction and continued until the end of surgery                   | KDIGO          | AKI; MV duration; ICU stay; hospital stay |
| Leino 2011    | Finland | CABG                     | Adult    | 35 vs. 31                       | NA           | 0.6 ng/ml           | Placebo | Started after anesthesia induction, and continued until 4h after arrival in the ICU | RIFLE          | AKI; MV duration            |
| Li 2017       | China   | Combined                 | Senior   | 142 vs. 143                     | NA           | 0.1–0.6 ug/kg/h/h   | Placebo | Started before surgery and continued until the end of MV                        | KDIGO          | AKI; MV duration; ICU stay; hospital stay; Mortality |
| Liu 2016      | China   | Combined                 | Adult    | 44 vs. 44                       | NA           | ≤ 1.5 ug/kg/h/h     | Propofol| Started upon arrival at the ICU and continued before extubation                | AKIN           | AKI; MV duration; ICU stay; hospital stay |
| Park 2014     | Korea   | Combined                 | Adult    | 67 vs. 75                       | 0.5 ug/kg    | 0.2–0.8 ug/kg/hr/hr | Remifentanil| Started upon return to the ICU and maintained until extubation                 | NA             | AKI; MV duration; ICU stay; hospital stay |
| Shehabi 2009  | Australia| Combined                 | Senior   | 149 vs. 146                     | NA           | 0.1–0.7 ug/kg/hr/ml | Morphine| Start within 1h of admission to the ICU until the removal of chest drains       | NA             | AKI; MV duration; ICU stay; hospital stay |
| Soh 2020      | Korea   | Combined                 | Senior   | 54 vs. 54                       | NA           | 0.4 ug/kg/ml        | Placebo | Started after anesthetic induction and continued for 24 h                       | KDIGO          | AKI; mortality              |
| Soliman 2016  | Egypt   | Aortic vascular surgery  | Adult    | 75 vs. 75                       | 1 ug/kg      | 0.3 ug/kg/h         | Placebo | Start before induction and maintained to the end of procedure                   | Cr > 115 μmol/L | AKI; mortality              |
| Soliman 2017  | Egypt   | CABG                     | Adult    | 75 vs. 75                       | NA           | 0.4 ug/kg           | Placebo | Started after induction and continued during the procedure and the first 24 postoperative hours | RIFLE          | AKI; ICU stay; hospital stay; mortality |
| Tang 2020     | China   | Cardiac valve replacement| Adult    | 38 vs. 37                       | 1 ug/kg      | 0.3 ug/kg/h         | Placebo | Started before induction and continued until the end of operation period        | KDIGO          | AKI; MV duration; ICU stay; hospital stay |
| Zhai 2017     | China   | Cardiac valve replacement| Adult    | 36 vs. 36                       | 0.6 ug/kg    | 0.2 ug/kg/h         | Placebo | Started before anesthesia and continued during the entire operation period      | RIFLE          | AKI; MV duration            |
Xiao et al. revealed that dexmedetomidine administration can protect organs only if administered before ischemia sets in [22]. In our meta-analysis, pooled results of 10 studies indicated that preoperative or intraoperative administration of dexmedetomidine cannot reduce the incidence of AKI compared with postoperative administration (\(p = 0.06\)). In addition, subgroup analysis suggested that the relatively low dose of dexmedetomidine (\(\leq 0.4 \mu g/kg/min\)) had a similar protective effect to the high dose (>0.4 \(\mu g/kg/min\); \(p = 0.46\)). Moreover, the previous meta-analysis suggested that the use of dexmedetomidine might reduce the incidence of AKI in adult patients [21,23]. However, they excluded children, which might conceal the true effect of dexmedetomidine on AKI, as the occurrence of AKI in children can also lead to adverse outcomes during the perioperative and postoperative periods. The present study showed no significant difference in the ability of dexmedetomidine to reduce AKI incidence between children and adults. Furthermore, both previous studies excluded trials involving patients with basic renal dysfunction, which might increase the heterogeneity among the studies. However, our results indicated that the inclusion of our study did not significantly increase heterogeneity (\(I^2 = 26\%\) vs. \(I^2 = 8\%\)). Linda et al. found that the increased prevalence of chronic kidney disease among elderly patients, excluding patients with renal dysfunction, might conceal the nephroprotective effect of dexmedetomidine in patients with CKD [24].

The current meta-analysis indicated that perioperative treatment with dexmedetomidine might reduce the incidence of delirium, consistent with the results of several other studies focusing on the incidence of delirium among patients undergoing cardiac surgery [25]. Lower rates of delirium have been reported in ICU patients sedated with dexmedetomidine than patients sedated with benzodiazepines and propofol [26,27]. Moreover, the incidences of arrhythmias, bradycardia, hypotension, and stroke were not significantly different in compared groups. These adverse events might prolong the length of stay in ICU and hospital and even increase the mortality rate. Hypotension and bradycardia are the most common adverse effects during the use of dexmedetomidine due to its inhibition of the sympathetic nervous system. Patients in the dexmedetomidine treatment group had a lower incidence of AKI despite more adverse hemodynamic events. However,

**Table 2. Subgroup analysis of the potential sources of heterogeneity.**

| Subgroup                          | Endpoint | No. of comparisons | OR  | WMD   | 95%CI   | \(p\) Value | \(I^2\) |
|-----------------------------------|----------|--------------------|-----|-------|--------|-------------|--------|
| Gender (males%)                   | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26          |
| \(\geq 50\)                       | AKI      | 13                 | 0.50| 0.37–0.68 | 0.084  | 38.6        |
| \(< 50\)                          | AKI      | 4                  | 0.35| 0.19–0.63 | 0.783  | 0.0         |
| Age (years)                       | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26          |
| \(\geq 60\)                       | AKI      | 6                  | 0.51| 0.35–0.73 | 0.188  | 33          |
| \(< 60\)                          | AKI      | 11                 | 0.43| 0.29–0.63 | 0.198  | 26.8        |
| DM (\(\geq 50\%\))               | AKI      | 14                 | 0.58| 0.47–0.73 | 0.215  | 22.6        |
| Yes                               | AKI      | 7                  | 0.45| 0.28–0.71 | 0.274  | 21.1        |
| No                                | AKI      | 7                  | 0.64| 0.50–0.82 | 0.304  | 16.6        |
| Hypertension (\(\geq 50\%\))     | AKI      | 12                 | 0.58| 0.46–0.74 | 0.159  | 30.2        |
| Yes                               | AKI      | 8                  | 0.58| 0.44–0.77 | 0.145  | 37.2        |
| No                                | AKI      | 4                  | 0.58| 0.37–0.92 | 0.189  | 37.2        |
| Surgical procedures (CABG \(\geq 50\%\)) | AKI    | 15                 | 0.55| 0.45–0.69 | 0.185  | 24.3        |
| Yes                               | AKI      | 7                  | 0.59| 0.44–0.80 | 0.138  | 38.2        |
| No                                | AKI      | 8                  | 0.52| 0.38–0.69 | 0.332  | 12.6        |
| CPB time (minutes)                | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26          |
| \(\geq 80\)                       | AKI      | 7                  | 0.42| 0.21–0.85 | 0.273  | 21.3        |
| \(< 80\)                          | AKI      | 10                 | 0.47| 0.36–0.63 | 0.125  | 35.3        |
| Control drugs                     | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26          |
| Placebo                           | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26          |
| Others                            | AKI      | 12                 | 0.48| 0.36–0.65 | 0.381  | 6.6         |
| Dexmedetomidine administration    | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26.0        |
| Pre/intraoperation                | AKI      | 11                 | 0.42| 0.32–0.56 | 0.107  | 37.7        |
| Postoperation                     | AKI      | 6                  | 0.92| 0.43–1.97 | 0.774  | 0.0         |
| Loading dose                      | AKI      | 17                 | 0.47| 0.36–0.61 | 0.161  | 26.0        |
| Yes                               | AKI      | 10                 | 0.56| 0.48–0.80 | 0.311  | 14.7        |
| No                                | AKI      | 7                  | 0.37| 0.25–0.55 | 0.226  | 26.5        |
| Dexmedetomidine dose (\(\leq 0.4 \mu g/kg/h\)) | AKI    | 10                 | 0.41| 0.31–0.54 | 0.670  | 0.0         |
| Yes                               | AKI      | 3                  | 0.61| 0.35–1.04 | 0.345  | 0.0         |
| No                                | AKI      | 7                  | 0.36| 0.26–0.51 | 0.839  | 0.0         |
Figure 2. Risk of bias assessment of the included studies.

Figure 3. Forest plots for meta-analysis of AKI incidence in cardiac surgery patients.
these adverse effects could be easily handled if the atropine or vasoactive agents were administrated timely. Findings from our meta-analysis showed a protective effect of dexmedetomidine on renal function in patients undergoing cardiac surgery. We comprehensively reviewed RCTs designed to detect the effect of dexmedetomidine on cardiac surgery patients, pediatric patients, and patients with renal impairment. The heterogeneity was 26% for the primary outcome, which suggested that the interpretation of the current finding was reliable.

The mean blood pressure may relatively decrease during CPB in cardiac surgery, and the blood pressure may return to normal after the CPB procedure. The protective effect of dexmedetomidine on attenuating the I/R injury in mice was related to sirtuin 3 activation [28]. Zhao et al. indicated that dexmedetomidine might reduce kidney injury by increasing autophagy through inhibition of the PI3K/AKT/mTOR pathway in lipopolysaccharide-induced rat AKI models [29]. However, further studies are needed to understand the exact mechanisms of the nephroprotective effects of dexmedetomidine.

The current study extends the scope of our understanding by summarizing the effect of dexmedetomidine on renal function after cardiac surgery. Several limitations exist in this meta-analysis. First, a previous study revealed that a higher incidence of AKI in patients with a long duration of cardiac surgery [30]. The duration of operation and ischemia might differ because the trials included in the previous meta-analysis were conducted at different medical centers, which could greatly affect renal function. Subgroup analysis suggested no significant difference in the AKI incidence between CPB time of more than 3 h or not. More eligible trials are required to further investigate the exact influence of CPB duration on the protective effect of dexmedetomidine. The same limitation was also noted for the length of MV duration, length of stay in ICU, and length of stay in hospital. Second, many factors could influence renal function, such as age, degree of hypertension, pulsatility of blood flow and central venous pressure during the surgery period, and drugs used for treating hypertension and diabetes mellitus; however, we only estimated the effect of dexmedetomidine. Further robust evidence is required to confirm the effect of dexmedetomidine on patients undergoing cardiac surgery. Third, based on the included data, there are four different definitions of AKI, including RIFLE, AKIN, KDIGO, and Cr > 115 µmol/L. There are still 4 studies that have not mentioned the definition of AKI. Indeed, a subgroup analysis based on AKI definition would be appropriate, but some of the subgroup analysis may only include 3 or less studies, too few studies might draw a misleading conclusion and this is a limitation of our study. Finally, some of the primary results were calculated based on the statistical methods of Luo et al. and Wan et al., which might influence the detection of differences in this study.

**Conclusion**

The perioperative administration of dexmedetomidine could reduce AKI incidence in patients undergoing cardiac surgery. Dexmedetomidine treatment may also reduce the length of stay in ICU and the incidence of postoperative delirium.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).
**Figure 5.** Forest plots for meta-analysis of adverse events (delirium, arrhythmias, bradycardia, hypotension, and stroke).
Funding
This work was funded by the joint foundation of Luzhou government and Southwest Medical University [NO.2017LZXNYD-J16, 2021LZXNYD-D08].

ORCID
Jianguo Feng http://orcid.org/0000-0002-5830-3317

References
[1] Engelman DT, Crisafi C, Germain M, et al. Using urinary biomarkers to reduce acute kidney injury following cardiac surgery. J Thorac Cardiovasc Surg. 2020;160(5):1235–1246.e1232.
[2] Katayama HT, Gomes B, Lobo C, for the BraSIS Study Group Investigators, et al. The effects of acute kidney injury in a multicenter cohort of high-risk surgical patients. Ren Fail. 2021;43(1):1338–1348.
[3] Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697–711.
[4] Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2019.
[5] Ammar A, Mahmoud K, Kasemy Z, et al. Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: a randomized controlled trial. Saudi J Anaesth. 2016 Oct-Dec;10(4):395–401.
[6] Soliman R, Hussien M. Comparison of the renoprotective effect of dexmedetomidine and dopamine in high-risk renal patients undergoing cardiac surgery: a double-blind randomized study. Ann Card Anaesth. 2017;20(4):408–415.
[7] Tang C, Hu Y, Gao J, et al. Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat. Life Sci. 2020;257:118004.
[8] Liu X, Zhang K, Wang W, et al. Dexmedetomidine sedation reduces atrial fibrillation after cardiac surgery compared to propofol: a randomized controlled trial. Crit Care. 2016;20(1):298.
[9] Djaini G, Silverton N, Fedorko L, et al. Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: a randomized controlled trial. Anesthesiology. 2016;124(2):362–368.
[10] Balkanay OO, Gokselde D, Omeroglu SN, et al. The dose-related effects of dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery bypass grafting: a randomized, triple-blind, placebo-controlled study. Interact CardioVasc Thorac Surg. 2015;20(2):209–214.
[11] Soh S, Shim JK, Song JW, et al. Effect of dexmedetomidine on acute kidney injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled trial. Br J Anaesth. 2020;124(4):386–394.
[12] Zhai M, Kang F, Han M, et al. The effect of dexmedetomidine on renal function in patients undergoing cardiac valve replacement under cardiopulmonary bypass: a double-blind randomized controlled trial. J Clin Anesth. 2017;40:33–38.
[13] Jo YY, Kim JY, Lee JY, et al. The effect of intraoperative dexmedetomidine on acute kidney injury after pediatric congenital heart surgery: a prospective randomized trial. Medicine. 2017;96(28):e7480.
[14] Kim EH, Lee JH, Kim HS, et al. Effects of intraoperative dexmedetomidine on the incidence of acute kidney injury in pediatric cardiac surgery patients: a randomized controlled trial. Paediatr Anaesth. 2020;30(10):1132–1138.
[15] Park JB, Bang SH, Chee HK, et al. Efficacy and safety of dexmedetomidine for postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg. 2014;47(3):249–254.
[16] Li X, Yang J, Nie XL, et al. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: a randomized controlled trial. PLoS One. 2017;12(2):e0170757.
[17] Soliman R, Zohry G. The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery. Ann Card Anaesth. 2016;19(4):606–613.
[18] Cho JS, Shim JK, Soh S, et al. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 2016;89(3):693–700.
[19] Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COMpared to Morphine-DEXCOM study). Anesthesiology. 2009;111(5):1075–1084.
[20] Leino K, Hynynen M, Jalonen J, the Dexmedetomidine in Cardiac Surgery Study Group, et al. Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study. BMC Anesthesiol. 2011;11(1):9.
[21] Peng K, Li D, Applegate RL, 2nd, et al. Effect of dexmedetomidine on cardiac Surgery-Associated acute kidney injury: a Meta-Analysis with trial sequential analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2020;34(3):603–613.
[22] Xiao J, Wan W, Zhang Y, et al. Administration of dexmedetomidine does not produce long-term protective effect on testicular damage post testicular Ischemia-Reperfusion injury. Drug Des Devel Ther. 2021;15:315–321.
[23] Liu Y, Sheng B, Wang S, et al. Dexmedetomidine prevents acute kidney injury after adult cardiac surgery: a meta-analysis of randomized controlled trials. BMC Anesthesiol. 2018;18(1):7.
[24] Bateman RM, Sharpe MD, Jagger JE, et al. 36th international symposium on intensive care and emergency medicine: Brussels, Belgium. 15–18 march 2016. Crit Care. 20:94.
[25] Turan A, Duncan A, Leung S, et al. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet. 2020;396(10245):177–185.
[26] Skrobik Y, Duprey MS, Hill NS, et al. Low-Dose nocturnal dexmedetomidine prevents ICU delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1147–1156.

[27] Pasin L, Landoni G, Nardelli P, et al. Dexmedetomidine reduces the risk of delirium, agitation and confusion in critically ill patients: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2014;28(6):1459–1466.

[28] Wang Z, Wu J, Hu Z, et al. Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting p75NTR-mediated oxidative stress and apoptosis. Oxid Med Cell Longev. 2020;2020:5454210.

[29] Zhao Y, Feng X, Li B, et al. Dexmedetomidine protects against Lipopolysaccharide-Induced acute kidney injury by enhancing autophagy through inhibition of the PI3K/AKT/mTOR pathway. Front Pharmacol. 2020;11:128.

[30] Ninni S, Seunes C, Ortmans S, et al. Peri-operative acute kidney injury upon cardiac surgery time-of-day. Int J Cardiol. 2018;272:54–59.